Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A recent phase III trial showed that the addition of bevacizumab, a monoclonal antibody to vascular endothelial growth factor-A, to first-line irinotecan, 5-fluorouracil, and leucovorin (IFL) prolonged median survival in patients with metastatic colorectal cancer. We carried out a retrospective analysis of patients in the trial to evaluate whether mutation status of k-ras, b-raf, or p53 or P53 expression could predict which patients were more likely to respond to bevacizumab. METHODS: Microdissected tumors from 295 patients (274 primary tumors, 21 metastases) were subject to DNA sequence analysis to identify mutations in k-ras, b-raf, and p53. Nuclear P53 expression was determined by immunohistochemistry. Hazard ratios and 95% confidence intervals (CI) for overall survival were estimated using Cox regression analysis. RESULTS: In all biomarker subgroups, estimated hazard ratios for risk of death were less than 1 for bevacizumab-treated patients as compared with those for placebo-treated patients. Mutations in k-ras and/or b-raf were observed in 88 of 213 patients (41%). Hazard ratios for death among patients with tumors with wild-type k-ras/b-raf status, as compared with those of patients with mutations in one or both genes, were 0.51 (95% CI = 0.28 to 0.95) among those treated with IFL plus bevacizumab and 0.66 (95% CI = 0.37 to 1.18) among those treated with IFL plus placebo. Mutations in p53 were found in 139 of 205 patients (68%), and P53 was overexpressed in 191 of 266 patients (72%); neither p53 mutation nor P53 overexpression was statistically significantly associated with survival. CONCLUSIONS: We did not find a statistically significant relationship between mutations of k-ras, b-raf, or p53 and the increase in median survival associated with the addition of bevacizumab to IFL in metastatic colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Watnick, R. S., Cheng, Y.-N., Rangarajan, A., Ince, T. A., & Weinberg, R. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00030-8 · Cited by 318
RetractedBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,463
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001) · Nature Medicine · doi:10.1038/87904 · Cited by 1,672
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P. A., Stratton, M. R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601894 · Cited by 1,267
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224
The Genetic Basis of Human Cancer
Vogelstein, B., & Kinzler, K. W. (1997) · Cited by 1,120
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon Cancer
Watanabe, T., Wu, T.-T., Catalano, P. J., Ueki, T., Satriano, R., Haller, D. G., Benson, A. B., & Hamilton, S. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104193441603 · Cited by 888
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872
Relf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 833
Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability
Eliceiri, B. P., Paul, R., Schwartzberg, P. L., Hood, J. D., Leng, J., & Cheresh, D. A. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80221-x · Cited by 813
CXC chemokines in angiogenesis
Belperio, J. A., Keane, M. P., Arenberg, D. A., Addison, C. L., Ehlert, J. E., Burdick, M. D., & Strieter, R. M. (2000) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.1.1 · Cited by 804
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1
Autiero, M., Waltenberger, J., Communi, D., Kranz, A., Moons, L., Lambrechts, D., Kroll, J., Plaisance, S., De Mol, M., Bono, F., et al. (2003) · Nature Medicine · doi:10.1038/nm884 · Cited by 773
Rak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
Morgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 652
Fiedler, W., Serve, H., Döhner, H., Schwittay, M., Ottmann, O. G., O'Farrell, A.-M., Bello, C. L., Allred, R., Manning, W. C., Cherrington, J. M., et al. (2005) · Blood · doi:10.1182/blood-2004-05-1846 · Cited by 490
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426
Yuen, S. T., Davies, H. R., Chan, T. L., Ho, J. W. C., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Tsui, W. W., Chan, A. S. Y., et al. (2002) · PubMed · Cited by 404
Hoos, A., Urist, M. J., Stojadinovic, A., Mastorides, S., Dudas, M. E., Leung, D. H. Y., Kuo, D., Brennan, M. F., Lewis, J. J., & Cordon-Cardo, C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64075-8 · Cited by 400
How to read a paper: Papers that report diagnostic or screening tests
Greenhalgh, T. (1997) · BMJ · doi:10.1136/bmj.315.7107.540 · Cited by 398
Inoue, M., Hager, J. H., Ferrara, N., Gerber, H.-P., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380
Greenhalgh, P., & Greenhalgh, T. (1999) · Cited by 342
Ahnen, D. J., Feigl, P., Quan, G., Fenoglio‐Preiser, C. M., Lovato, L., Bunn, P. A., Stemmerman, G. N., Wells, J. D., Macdonald, J. S., & Meyskens, F. L. (1998) · PubMed · Cited by 338
P53 abnormalities and outcomes in colorectal cancer: a systematic review
Munro, A. J., Lain, S., & Lane, D. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602358 · Cited by 289
Rak, J. W., Mitsuhashi, Y., Sheehan, C., Tamir, A., Viloria‐Petit, A., Filmus, J., Mansour, S. J., Ahn, N. G., & Kerbel, R. S. (2000) · PubMed · Cited by 288
Allegra, C. J., Paik, S., Colangelo, L. H., Parr, A. L., Kirsch, I., Kim, G., Klein, P., Johnston, P. G., Wolmark, N., & Wieand, H. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.044 · Cited by 282
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
Fransen, K. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh049 · Cited by 268
CEA-Related Cell Adhesion Molecule 1
Ergün, S., Kilic, N., Ziegeler, G., Hansen, A., Nollau, P., Götze, J., Wurmbach, J.-H., Horst, A., Weil, J., Fernando, M., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80426-8 · Cited by 248
Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer
Bell, S. M., Scott, N., Cross, D., Sagar, P., Lewis, F. A., Blair, G. E., Taylor, G. R., Dixon, M. F., & Quirke, P. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90835-z · Cited by 245
Bouvet, M., Ellis, L. M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C. D., Fang, B., Lee, J. J., & Roth, J. A. (1998) · PubMed · Cited by 242
K-ras and p16 Aberrations Confer Poor Prognosis in Human Colorectal Cancer
Esteller, M., González, S., Risques, R. A., Marcuello, E., Mangues, R., Germà, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.299 · Cited by 234
Bazan, V., Migliavacca, M., Zanna, I., Tubiolo, C., Grassi, N., Latteri, M. A., La Farina, M., Albanese, I., Dardanoni, G., Salerno, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf226 · Cited by 225
Nitti, D., Belluco, C., Montesco, M. C., Bertorelle, R., Pian, P. P. D., Fassina, A., Ninfo, V., Chieco‐Bianchi, L., & Lise, M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10165-4 · Cited by 223
Walker, D. R., Bond, J. P., Tarone, R. E., Harris, C. C., Makalowski, W., Boguski, M. S., & Greenblatt, M. S. (1999) · Oncogene · doi:10.1038/sj.onc.1202298 · Cited by 198
Barratt, P., Seymour, M., Stenning, S., Georgiades, I., Walker, C., Birbeck, K., & Quirke, P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11402-4 · Cited by 194
Ikenoue, T., Hikiba, Y., Kanai, F., Tanaka, Y., Imamura, J., Imamura, T., Ohta, M., Ijichi, H., Tateishi, K., Kawakami, T., et al. (2003) · PubMed · Cited by 164
Jubb, A. M., Pham, T. Q., Hanby, A. M., Frantz, G. D., Peale, F. V., Wu, T. D., Koeppen, H. W., & Hillan, K. J. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.012963 · Cited by 163
Self-citationSoong, R., Robbins, P., Dix, B. R., Grieu, F., Lim, B. H. G., Knowles, S., Williams, K. E., Turbett, G. R., House, A. K., & Iacopetta, B. J. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90282-8 · Cited by 147
Prognostic significance of p53 mutations in colon cancer at the population level
Samowitz, W. S., Curtin, K., Ma, K., Edwards, S., Schaffer, D., Leppert, M. F., & Slattery, M. L. (2002) · International Journal of Cancer · doi:10.1002/ijc.10405 · Cited by 128
Strickland, L. A., Jubb, A. M., Hongo, J., Zhong, F., Burwick, J., Fu, L., Frantz, G. D., & Koeppen, H. (2005) · The Journal of Pathology · doi:10.1002/path.1805 · Cited by 116
Self-citationGervaz, P., Bouzourène, H., Cerottini, J., Chaubert, P., Benhattar, J., Secic, M., Wexner, S. D., Givel, J., & Belin, B. M. (2001) · Diseases of the Colon & Rectum · doi:10.1007/bf02234734 · Cited by 108
p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Soong, R., Grieu, F., Robbins, P., Dix, B. R., Chen, D., Parsons, R. E., House, A. K., & Iacopetta, B. M. (1997) · PubMed · Cited by 101
Picon, A. I., Gold, L. I., Wang, J., Cohen, A. M., & Friedman, E. D. (1998) · PubMed · Cited by 100
Kandioler, D., Zwrtek, R., Ludwig, C., Janschek, E., Ploner, M., Hofbauer, F., Kührer, I., Kappel, S., Wrba, F., Horvath, M., et al. (2002) · Annals of Surgery · doi:10.1097/00000658-200204000-00006 · Cited by 90
Belluco, C., Guillem, J. G., Kemeny, N. E., Huang, Y., Klimstra, D. S., Berger, M. F., & Cohen, A. M. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2696 · Cited by 76
Bras-Gonçalves, R., Rosty, C., Laurent‐Puig, P., Soulié, P., Dutrillaux, B., & Poupon, M. F. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1019 · Cited by 75
p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer
Adell, G., Sun, X., Stål, O., Klintenberg, C., Sjödahl, R. I., & Nordenskjöld, B. A. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00041-9 · Cited by 70
Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer
Kaserer, K., Schmaus, J., Bethge, U., Migschitz, B., Fasching, S., Walch, A., Herbst, F., Teleky, B., & Wrba, F. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200003)190:4<450::aid-path545>3.0.co;2-8 · Cited by 70
Tollenaar, R., van Krieken, J., van Slooten, H.-J., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.306 · Cited by 68
Haraguchi, M., Komuta, K., Akashi, A., Matsuzaki, S., Furui, J., & Kanematsu, T. (2002) · Oncology Reports · doi:10.3892/or.9.1.159 · Cited by 63
Ikeda, N., Nakajima, Y., Sho, M., Adachi, M., Huang, C., Iki, K., Kanehiro, H., Hisanaga, M., Nakano, H., & Miyake, M. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3<488::aid-cncr1347>3.0.co;2-f · Cited by 54
Rosty, C., Chazal, M., Étienne-Grimaldi, M.-C., Létoublon, C., Bourgeon, A., Delpéro, J., Pezet, D., Beaune, P. H., Laurent‐Puig, P., & Milano, G. A. (2001) · International Journal of Cancer · Cited by 50
Shi, Y., & Ferrara, N. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9966 · Cited by 39
Jubb, A. M., Landon, T., Burwick, J. A., Pham, T. Q., Frantz, G. D., Cairns, B., Quirke, P., Peale, F. V., & Hillan, K. (2003) · The Journal of Pathology · doi:10.1002/path.1371 · Cited by 39
Self-citationDaldrup-Link, H. E., Okuhata, Y., WOLFE, A., SRIVASTAV, S., ØIE, S., FERRARA, N., Cohen, R. L., Shames, D. M., & Brasch, R. C. (2004) · Microcirculation · doi:10.1080/10739680490457665 · Cited by 36
Bazan, V., Migliavacca, M., Tubiolo, C., et al. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10088 · Cited by 23
Comparison of anti-p53 antibodies in immunoblotting
Turpeinen, M., Serpi, R., Rahkolin, M., & Vähäkangas, K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00298-x · Cited by 14
Nemunaitis, J. J., Cox, J. V., Hays, S., Meyer, W., Kebart, R., Ognoskie, N., Courtney, A., Yu, Y., Rasmussen, H. S., & Tong, A. (2000) · Cancer Investigation · doi:10.3109/07357900009031822 · Cited by 9
Cited by
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
The Chromosomal Instability Pathway in Colon Cancer
Pino, M. S., & Chung, D. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.065 · Cited by 932
Metadata
- Authors
- Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., & Koeppen, H.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-06
- Volume
- 97
- Issue
- 13
- Pages
- 981-989
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2101144899
- Cited by
- 319
- References
- 71
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.